Literature DB >> 24184489

Drug delivery design for intravenous route with integrated physicochemistry, pharmacokinetics and pharmacodynamics: illustration with the case of taxane therapeutics.

L Harivardhan Reddy1, Didier Bazile2.   

Abstract

This review is aimed at combining the published data on taxane formulations into a generalized Drug Delivery approach, starting from the physicochemistry and assessing its relationships with the pharmacokinetics, the biodistribution and the pharmacodynamics. Owing to the number and variety of taxane formulation designs, we considered this class of cytotoxic anticancer agents of particular interest to illustrate the concepts attached to this approach. According to the history of taxane development, we propose a classification as (i) "surfactant-based formulations" first generation, (ii) "surfactant-free formulations" second generation and (iii) "modulated pharmacokinetics drug delivery systems" third generation. Since our objective was to make the link between (i) the physicochemistry of the drug and carrier and (ii) the efficacy and safety of the drug in preclinical animal models and (iii) in human, we focused on the drug delivery technologies that were tested in clinic.
© 2013.

Entities:  

Keywords:  Biopharmacy; Cabazitaxel; Classification; Docetaxel; Drug delivery systems design; Efficacy; Nanoparticles; Paclitaxel; Pharmacodynamics; Pharmacokinetics; Physicochemistry; Safety; Taxanes

Mesh:

Substances:

Year:  2013        PMID: 24184489     DOI: 10.1016/j.addr.2013.10.007

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  8 in total

1.  Drug-Polymer Interaction, Pharmacokinetics and Antitumor Effect of PEG-PLA/Taxane Derivative TM-2 Micelles for Intravenous Drug Delivery.

Authors:  Qiao Wang; Yi Liu; Chenguang Pu; Hongjuan Zhang; Xinyi Tan; Jingxin Gou; Haibing He; Tian Yin; Yu Zhang; Yanjiao Wang; Xing Tang
Journal:  Pharm Res       Date:  2018-09-13       Impact factor: 4.200

2.  PEGylated lipid microspheres loaded with cabazitaxel for intravenous administration: stability, bioavailability, antitumor efficacy, and toxicity.

Authors:  Yang Liu; Bin Xie; Lin Li; Xinyu Zhang; Yu Zhang; Haibing He; Tian Yin; Xing Tang; Cuifang Cai; Jingxin Gou
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

3.  Cholic acid-based novel micellar nanoplatform for delivering FDA-approved taxanes.

Authors:  Gaurav Bharadwaj; Viet Nhan; ShanChao Yang; Xiaocen Li; Anand Narayanan; Ana Carolina Macarenco; Yu Shi; Darrion Yang; Letícia Salvador Vieira; Wenwu Xiao; Yuanpei Li; Kit S Lam
Journal:  Nanomedicine (Lond)       Date:  2017-04-27       Impact factor: 5.307

4.  A method to Quantify the Affinity of Cabazitaxel for PLA-PEG Nanoparticles and Investigate the Influence of the Nano-Assembly Structure on the Drug/Particle Association.

Authors:  O Diou; S Greco; T Beltran; D Lairez; J-R Authelin; D Bazile
Journal:  Pharm Res       Date:  2015-04-22       Impact factor: 4.200

5.  Cabazitaxel-loaded human serum albumin nanoparticles as a therapeutic agent against prostate cancer.

Authors:  Na Qu; Robert J Lee; Yating Sun; Guangsheng Cai; Junyang Wang; Mengqiao Wang; Jiahui Lu; Qingfan Meng; Lirong Teng; Di Wang; Lesheng Teng
Journal:  Int J Nanomedicine       Date:  2016-07-26

6.  Nano-sized cytochrome P450 3A4 inhibitors to block hepatic metabolism of docetaxel.

Authors:  Marion Paolini; Laurence Poul; Céline Berjaud; Matthieu Germain; Audrey Darmon; Maxime Bergère; Agnès Pottier; Laurent Levy; Eric Vibert
Journal:  Int J Nanomedicine       Date:  2017-08-02

7.  Nanoscale isoindigo-carriers: self-assembly and tunable properties.

Authors:  Tatiana N Pashirova; Andrei V Bogdanov; Lenar I Musin; Julia K Voronina; Irek R Nizameev; Marsil K Kadirov; Vladimir F Mironov; Lucia Ya Zakharova; Shamil K Latypov; Oleg G Sinyashin
Journal:  Beilstein J Nanotechnol       Date:  2017-02-01       Impact factor: 3.649

Review 8.  Nanomedicine and versatile therapies for cancer treatment.

Authors:  Aparna Shukla; Pralay Maiti
Journal:  MedComm (2020)       Date:  2022-08-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.